AMG Announces Partnership with Forbion - Seite 2

“We are excited to partner with AMG, as its unique approach enables us at Forbion to preserve our investment independence and operational autonomy,” said Sander Slootweg, co-founder and Managing Partner of Forbion. “Our entrepreneurial and investment-centric culture has been critical to our success, and with our respective firms’ long-term partnership orientation, Forbion and AMG share a deep cultural alignment. As we continue to invest in high-quality life sciences companies, we are confident that our strategic partnership with AMG will enhance our ability to further expand our investment platform, diversify our client base as we access new geographies and channels through AMG’s capital formation capabilities, and build an enduring, multi-generational firm.”

The terms of the transaction were not disclosed. The transaction is expected to close in the second half of 2023.

About AMG

AMG is a leading partner to independent investment management firms globally. AMG’s strategy is to generate long-term value by investing in a diverse array of high-quality independent partner-owned firms, through a proven partnership approach, and allocating resources across AMG’s unique opportunity set to the areas of highest growth and return. AMG’s innovative partnership approach enables each Affiliate’s management team to own significant equity in their firm while maintaining operational and investment autonomy. In addition, AMG offers its Affiliates growth capital, distribution, and other strategic value-added capabilities, which enhance the long-term growth of these independent businesses, and enable them to align equity incentives across generations of principals to build enduring franchises. As of March 31, 2023, AMG’s aggregate assets under management were approximately $668 billion across a broad range of differentiated investment strategies. For more information, please visit the Company’s website at www.amg.com

About Forbion

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany, and Singapore. Forbion invests in life sciences companies that are active in the biopharmaceutical space, managing €3 billion across multiple fund strategies that cover all stages of biopharmaceutical drug development. The firm’s current team consists of more than 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with investments in 95 companies across 8 funds. Forbion’s record of sourcing, building and guiding life sciences companies has resulted in many breakthrough therapies and valuable exits. In addition to its financial return objectives, Forbion selects investments that will positively affect the health and well-being of patients. The firm is a signatory to the United Nations Principles for Responsible Investment. More information can be found at www.forbion.com